Skip to content. | Skip to navigation

European Coalition on Homeopathic & Anthroposophic Medicinal Products

Navigation

Study report on Availability of medicines includes situation of homeopathic and anthroposophic medicinal products

02 Dec 2014

ECHAMP warmly welcomes the publication of the ‘External Study Report on the Availability of Medicinal Products for Human Use,’ which gives significant prominence, for the first time, to the situation concerning the availability of homeopathic and anthroposophic medicinal products in the EU. Although the report contains some statements that are not fully correct from ECHAMP's point of view, the overall positive aspects clearly outweigh the deficits.

The long-awaited study investigates the availability of medicinal products for human use in the EU and EEA, focusing on the authorisation procedures for medicinal products. It investigates different reasons for lack of availability and the effectiveness of existing European legislative provisions in addressing these problems, exploring six case studies, including the use of Article 126a of Directive 2001/83/EC (Cyprus Clause) and the availability of herbal, homeopathic and anthroposophic medicinal products.

The study quotes ECHAMP’s own report ‘The Availability of Homeopathic and Anthroposophic Medicinal Products in the EU’ as its main source of information on this topic. ECHAMP is now working hard to analyse the new report and we will share our conclusions with Members before Christmas. For now, we welcome the fact that the report acknowledges the need to improve the national implementation of simplified procedures for homeopathic and anthroposophic medicinal products as one example of a specific area for improvement.

This study report is presented as a working document of the Pharmaceutical committee, an advisory Committee to the Commission that consists of senior experts in public health matters from the Member States' administrations; it is an independently written document, which means it does not necessarily reflect the official opinion of the European Commission. Nevertheless, it is hoped it will add significant weight to ECHAMP’s goal of suitable regulation for our products.